Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NMRA
NMRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NMRA News
Neumora Therapeutics to Participate in Healthcare Conference
Apr 06 2026
Newsfilter
Schall Law Firm Investigates Neumora Securities Violations
Apr 01 2026
Globenewswire
Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment
Mar 31 2026
Yahoo Finance
Neumora Therapeutics Reports Q4 Earnings Miss and Financial Guidance
Mar 30 2026
seekingalpha
Schall Law Firm Investigates Neumora Therapeutics for Securities Violations
Mar 25 2026
Globenewswire
NMRA-511 Shows Promising Results in Alzheimer's Agitation
Feb 17 2026
Benzinga
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
Jan 07 2026
Benzinga
Neumora Reports NMRA-511 Alzheimer’s Study Results, Significantly Improves Patient Behavior
Jan 05 2026
Benzinga
Neumora (NMRA) Reports Positive Phase 1b Results for NMRA-511 in Alzheimer's Agitation
Jan 05 2026
NASDAQ.COM
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
Dec 23 2025
Benzinga
Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill
Dec 23 2025
NASDAQ.COM
Analyst Recognizes Potential in Neumora's Growing Obesity and Metabolic Portfolio
Dec 01 2025
Benzinga
Neumora Receives Upgrade from RBC Capital Markets Due to Obesity and Parkinson's Drug Potential
Dec 01 2025
SeekingAlpha
Chevron Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday
Dec 01 2025
Benzinga
RBC Capital Boosts Neumora Therapeutics Rating to Outperform and Increases Price Target to $7
Dec 01 2025
Benzinga
Show More News
